Completed PHASE4 INTERVENTIONAL 2-arm NCT02097719

Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Sponsor: Allergan

Interventions bimatoprost 0.01% hypromellose 0.3% timolol 0.5% travoprost 0.004%

Updated 6 times since 2017 Last updated: Dec 9, 2015 Started: May 31, 2014 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02097719, this PHASE4 trial focuses on Glaucoma and Ocular Hypertension and remains completed. Sponsored by Allergan, it has been updated 6 times since 2014, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

May 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allergan

Data source: Allergan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Racine, United States